496 related articles for article (PubMed ID: 32198625)
21. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
22. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
Zhang S; Shen J; Li D; Cheng Y
Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo.
Chang H; Yi B; Ma R; Zhang X; Zhao H; Xi Y
Sci Rep; 2016 Feb; 6():22312. PubMed ID: 26924382
[TBL] [Abstract][Full Text] [Related]
24. Simplified CRISPR-Mediated DNA Editing in Multicellular Eukaryotes.
Kumar R; Tiwari K; Saudagar P
Methods Mol Biol; 2023; 2575():241-260. PubMed ID: 36301478
[TBL] [Abstract][Full Text] [Related]
25. In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia.
Pan X; Philippen L; Lahiri SK; Lee C; Park SH; Word TA; Li N; Jarrett KE; Gupta R; Reynolds JO; Lin J; Bao G; Lagor WR; Wehrens XHT
Circ Res; 2018 Sep; 123(8):953-963. PubMed ID: 30355031
[TBL] [Abstract][Full Text] [Related]
26. CRISPR/Cas9 in Genome Editing and Beyond.
Wang H; La Russa M; Qi LS
Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843
[TBL] [Abstract][Full Text] [Related]
27. A Single Transcript CRISPR-Cas9 System for Multiplex Genome Editing in Plants.
Tang X; Zhong Z; Ren Q; Liu B; Zhang Y
Methods Mol Biol; 2019; 1917():75-82. PubMed ID: 30610629
[TBL] [Abstract][Full Text] [Related]
28. In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications.
Huang K; Zapata D; Tang Y; Teng Y; Li Y
Biomaterials; 2022 Dec; 291():121876. PubMed ID: 36334354
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Genome Editing and its Potential Enhancement through CRISPR Guide RNA and Cas9 Modifications.
Batzir NA; Tovin A; Hendel A
Pediatr Endocrinol Rev; 2017 Jun; 14(4):353-363. PubMed ID: 28613045
[TBL] [Abstract][Full Text] [Related]
30. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
Sarkar E; Khan A
Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
[TBL] [Abstract][Full Text] [Related]
31. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells.
Donohoue PD; Pacesa M; Lau E; Vidal B; Irby MJ; Nyer DB; Rotstein T; Banh L; Toh MS; Gibson J; Kohrs B; Baek K; Owen ALG; Slorach EM; van Overbeek M; Fuller CK; May AP; Jinek M; Cameron P
Mol Cell; 2021 Sep; 81(17):3637-3649.e5. PubMed ID: 34478654
[TBL] [Abstract][Full Text] [Related]
32. Genome Editing with CRISPR-Cas9: Can It Get Any Better?
Haeussler M; Concordet JP
J Genet Genomics; 2016 May; 43(5):239-50. PubMed ID: 27210042
[TBL] [Abstract][Full Text] [Related]
33. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
[TBL] [Abstract][Full Text] [Related]
34. CRISPR-Cas9 gene editing induced complex on-target outcomes in human cells.
Wen W; Zhang XB
Exp Hematol; 2022 Jun; 110():13-19. PubMed ID: 35304271
[TBL] [Abstract][Full Text] [Related]
35. CRISPR/Cas9 with single guide RNA expression driven by small tRNA promoters showed reduced editing efficiency compared to a U6 promoter.
Wei Y; Qiu Y; Chen Y; Liu G; Zhang Y; Xu L; Ding Q
RNA; 2017 Jan; 23(1):1-5. PubMed ID: 27742910
[TBL] [Abstract][Full Text] [Related]
36. Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity.
Basila M; Kelley ML; Smith AVB
PLoS One; 2017; 12(11):e0188593. PubMed ID: 29176845
[TBL] [Abstract][Full Text] [Related]
37. CRISPR/Cas system: A game changing genome editing technology, to treat human genetic diseases.
Hussain W; Mahmood T; Hussain J; Ali N; Shah T; Qayyum S; Khan I
Gene; 2019 Feb; 685():70-75. PubMed ID: 30393194
[TBL] [Abstract][Full Text] [Related]
38. Development of an Agrobacterium-delivered CRISPR/Cas9 system for wheat genome editing.
Zhang Z; Hua L; Gupta A; Tricoli D; Edwards KJ; Yang B; Li W
Plant Biotechnol J; 2019 Aug; 17(8):1623-1635. PubMed ID: 30706614
[TBL] [Abstract][Full Text] [Related]
39. Low incidence of SNVs and indels in trio genomes of Cas9-mediated multiplex edited sheep.
Wang X; Liu J; Niu Y; Li Y; Zhou S; Li C; Ma B; Kou Q; Petersen B; Sonstegard T; Huang X; Jiang Y; Chen Y
BMC Genomics; 2018 May; 19(1):397. PubMed ID: 29801435
[TBL] [Abstract][Full Text] [Related]
40. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.
He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ
Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
